Clinical trial
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients…
NCT00369564 · University of South Florida, Other · Completed
Key facts
| NCT number | NCT00369564 |
|---|---|
| Title | Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer |
| Official title | Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer |
| Lead sponsor | University of South Florida, Other |
| Collaborators | National Cancer Institute (NCI) NIH Children's Oncology Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma |
| Intervention type | Drug, Other |
| Interventions | glutamic acid, placebo |
| Enrollment | 250 |
| Start date | May 1, 2007 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Aug 29, 2006 |
| Last update posted | Aug 11, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: